Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC by Imai-Nishiya, Harue et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
Double knockdown of α1,6-fucosyltransferase (FUT8) and 
GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: 
a new strategy for generating fully non-fucosylated therapeutic 
antibodies with enhanced ADCC
Harue Imai-Nishiya, Katsuhiro Mori, Miho Inoue, Masako Wakitani, 
Shigeru Iida, Kenya Shitara and Mitsuo Satoh*
Address: Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., 3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533, Japan
Email: Harue Imai-Nishiya - harue.imai@kyowa.co.jp; Katsuhiro Mori - mkatsu@kyowa.co.jp; Miho Inoue - miho.inoue@kyowa.co.jp; 
Masako Wakitani - masako.wakitani@kyowa.co.jp; Shigeru Iida - s.iida@kyowa.co.jp; Kenya Shitara - kshitara@kyowa.co.jp; 
Mitsuo Satoh* - msatoh@kyowa.co.jp
* Corresponding author    
Abstract
Background: Antibody-dependent cellular cytotoxicity (ADCC) is greatly enhanced by the absence of the core
fucose of oligosaccharides attached to the Fc, and is closely related to the clinical efficacy of anticancer activity in
humans in vivo. Unfortunately, all licensed therapeutic antibodies and almost all currently-developed therapeutic
antibodies are heavily fucosylated and fail to optimize ADCC, which leads to a large dose requirement at a very
high cost for the administration of antibody therapy to cancer patients. In this study, we explored the possibility
of converting already-established antibody-producing cells to cells that produce antibodies fully lacking core
fucosylation in order to facilitate the rapid development of next-generation therapeutic antibodies.
Results: Firstly, loss-of-function analyses using small interfering RNAs (siRNAs) against the three key genes
involved in oligosaccharide fucose modification, i.e. α1,6-fucosyltransferase (FUT8), GDP-mannose 4,6-
dehydratase (GMD), and GDP-fucose transporter (GFT), revealed that single-gene knockdown of each target was
insufficient to completely defucosylate the products in antibody-producing cells, even though the most effective
siRNA (>90% depression of the target mRNA) was employed. Interestingly, beyond our expectations, synergistic
effects of FUT8 and GMD siRNAs on the reduction in fucosylation were observed, but not when these were used
in combination with GFT siRNA. Secondly, we successfully developed an effective short hairpin siRNA tandem
expression vector that facilitated the double knockdown of FUT8 and GMD, and we converted antibody-producing
Chinese hamster ovary (CHO) cells to fully non-fucosylated antibody producers within two months, and with
high converting frequency. Finally, the stable manufacture of fully non-fucosylated antibodies with enhanced
ADCC was confirmed using the converted cells in serum-free fed-batch culture.
Conclusion: Our results suggest that FUT8 and GMD collaborate synergistically in the process of intracellular
oligosaccharide fucosylation. We also demonstrated that double knockdown of FUT8 and GMD in antibody-
producing cells could serve as a new strategy for producing next-generation therapeutic antibodies fully lacking
core fucosylation and with enhanced ADCC. This approach offers tremendous cost- and time-sparing advantages
for the development of next-generation therapeutic antibodies.
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Background
Antibodies of the human IgG1 isotype containing two
biantennary complex-type N-linked oligosaccharides in
the constant region (Fc) [1] are commonly used therapeu-
tically. As regards cancer treatment in particular, the anti-
body effector function of antibody-dependent cellular
cytotoxicity (ADCC) is known to be important and is
closely related to clinical efficacy in humans in vivo [2-4].
Through the Fc, therapeutic antibodies can mediate effec-
tor functions, and ADCC is greatly influenced by Fc oli-
gosaccharide structure [5,6]. Removal of the core fucose
from Fc oligosaccharides is widely recognized as being
important for the effector function of ADCC [7,8]. Anti-
bodies in which the Fc oligosaccharide structure lacks the
core fucose exhibit more potent efficacy than do fuco-
sylated antibodies, both in vitro and in vivo [9-13]. Thera-
peutic antibodies fully lacking core fucosylation are able
to escape the inhibitory effects of both human serum IgG
and other contaminating fucosylated antibody ingredi-
ents to achieve optimal ADCC [6,14-17]. Unfortunately,
almost all licensed therapeutic antibodies developed to
date are heavily fucosylated, i.e., the majority of antibody
molecules possess Fc oligosaccharides with the core
fucose [18,19], which results in a failure to optimize
ADCC. The presence of this core fucose is largely due to
the fact that the antibodies are produced by rodent mam-
malian cell lines with intrinsic fucosyltransferase activity
(e.g., Chinese hamster ovary (CHO), mouse myeloma
NS0 and SP2/0, and mouse hybridoma cell lines).
In mammalian cells, core fucosylation of the Fc oligosac-
charides is mediated by the only gene, α1,6-fucosyltrans-
ferase (FUT8), that catalyzes the transfer of fucose from
GDP-fucose to the innermost N-acetylglucosamine (Glc-
NAc) of Fc oligosaccharides via an α1,6-linkage [20]. The
intracellular GDP-fucose, an essential substrate of oli-
gosaccharide fucosylation, is synthesized in the cytoplasm
via both a de novo pathway and the salvage pathway
shown in Fig. 1. The de novo pathway transforms GDP-
mannose, which originates from D-glucose taken into the
Oligosaccharide fucosylation and GDP-fucose synthesis in mammalian cells Figure 1
Oligosaccharide fucosylation and GDP-fucose synthesis in mammalian cells. In mammalian cells, GDP-fucose is syn-
thesized via two distinct pathways, the de novo and salvage pathways. The transport of GDP-fucose into the Golgi apparatus, 
where the fucosyltransferases are located, is accomplished by a GDP-fucose transporter.
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cytoplasm from the extracellular environment, to GDP-
fucose, via three enzymatic reactions carried out by two
proteins: GDP-mannose 4,6-dehydratase (GMD) and
GDP-keo-6-deoxymannose 3,5-epimerase, 4-reductase
(FX) [21,22]. The salvage pathway synthesizes GDP-
fucose from free L-fucose derived from extracellular or lys-
osomal sources. Most of the intracellular GDP-fucose is
generated via the de novo pathway, and the metabolite-free
L-fucose is also reutilized through the salvage pathway
[22]. The GDP-fucose, which accumulates in the cyto-
plasm, is transported into the lumen of the Golgi appara-
tus by a GDP-fucose transporter (GFT) anchored at the
Golgi membrane [23], and then serves as a substrate in the
synthesis of fucosylated glycoconjugates by fucosyltrans-
ferases [22,24,25].
To date, only a few studies have addressed the regulation
of Fc oligosaccharide fucosylation in mammalian cells
using the following approaches: 1) the application of a
mutant CHO cell line, Lec13, partially deficient in GMD
[7] or that of a rat hybridoma cell line, YB2/0 [8], as host
cells; 2) the introduction of a small interfering RNA
(siRNA) against FUT8 [26]; and 3) the co-expression of β-
1,4-N-acetylglucosaminyltransferase III (GnT-III) and
Golgi α-mannosidase II (ManII) [27]. Of these, the gene
knockout of FUT8 and GMD is the only strategy for man-
ufacturing fully non-fucosylated recombinant therapeu-
tics in mammalian cells [28-30]. However, gene targeting
in mammalian somatic cells is difficult to achieve and is a
laborious and time-consuming process, because in
somatic cells, non-homologous recombination events
occur several orders of magnitude more frequently than
homologous recombination [28,31]. Thus, gene targeting
in mammalian somatic cells remains very difficult to
apply to each antibody-producing clone as a simple
means of controlling fucosylation.
In this study, we explored the possibility of the high-fre-
quency conversion of already-established antibody-pro-
ducing cells (1st-generation) to cells that produce
antibodies fully lacking core fucosylation (2nd-genera-
tion) within a few months. Moreover, it was considered
industrially useful to generate 2nd-generation cells that
would yield the equivalent antibody productivity of the
original cells, without inducing any changes in cell char-
acter beyond the lack of fucosylation. To this end, we
applied an RNA interference (RNAi) technique in combi-
nation with a cellular phenotypic selection strategy using
Lens culinaris agglutinin (LCA) lectin, which recognizes
the  α1,6 fucosylated trimannose-core structure of N-
linked oligosaccharides and commits cells expressing this
structure to a cell-death pathway. In our previous study,
single-gene knockdown of FUT8 resulted in a substantial,
but not full, reduction of antibody fucosylation in the
products [26]. Here, we identified synergistic effects of the
double knockdown of FUT8 and GMD on oligosaccharide
fucosylation in mammalian cells. This finding enabled us
to design a new conversion strategy for the manufacture of
next-generation therapeutic antibodies fully lacking core
fucosylation and with enhanced ADCC.
Results
Single gene knockdown of FUT8, GMD, and GFT in 
antibody-producing cells
Three constitutive short hairpin siRNA expression vectors
against Chinese hamster FUT8, GMD, and GFT were gen-
erated and introduced into an IgG1 antibody-producing
CHO/DG44 clone, 32-05-12 [26], to evaluate the effects
of target gene knockdown on the levels of fucosylation of
the products. Puromycin-resistant clones transformed by
the vectors appeared after transfection with a transforma-
tion efficiency of approximately 1,300 per 1.6 × 106 elec-
troporated cells, irrespective of the vector differences.
However, subsequent selection of LCA-resistant clones
showed clear differences in the appearance of surviving
colonies. The ratios of LCA-resistant clones to puromycin-
resistant clones transformed by the three siRNA expres-
sion vectors against FUT8, GMD, and GFT were 11.5%,
14.8%, and 0.8%, respectively (Table 1). The resultant
LCA-resistant clones were expanded in medium without
LCA, and the mRNA expression of FUT8, GMD, and GFT,
as well as the oligosaccharide structure of the antibodies
produced in these clones, were quantitatively analyzed.
The target gene mRNA was reduced to a level exceeding
90% in clones appearing in all three siRNA-introduced
transformants; however, in none of the clones was Fc oli-
gosaccharide fucosylation completely abolished. The
most effective rates of reduction in fucosylation among
Table 1: Ratio of LCA-resistant clones to drug-resistant clones transformed by the introduction of siRNA expression vectors
Vector Target mRNA Drugr clonesa LCAr clonesb % LCAr/Drugr
FUT8shRNA/lib3/pPUR FUT8 1344 155 11.5
pPUR/GMDshB GMD 1440 213 14.8
GFT_3G10/pPUR GFT 1296 11 0.8
FT8lib3_GMDB/pAGE GMD·FUT8 1500 730 48.7
aDrugr, puromycin resistance or hygromycin resistance.
bLCAr, LCA resistanceBMC Biotechnology 2007, 7:84 http://www.biomedcentral.com/1472-6750/7/84
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the clones transformed by the FUT8,  GMD, and GFT
siRNA expression vectors were approximately 72%, 79%,
and 42%, respectively.
Synergistic effects of double knockdown of FUT8 and 
GMD on fucosylation
To explore the effects of double knockdown of the target
genes  FUT8  and  GMD, two GMD  siRNA-introduced
clones exhibiting a maximum reduction in product fuco-
sylation, designated as GMDb2 and GMDb5, were
selected and re-electroporated with the FUT8  siRNA
expression vector. LCA-resistant clones were selected in
the presence of 100 μM L-fucose after drug-resistant selec-
tion had been carried out, and two clones expressing
highly non-fucosylated antibodies were selected inde-
pendently from each GMD siRNA-introduced clone in the
medium. In the four established clones, the FUT8 mRNA
expression levels decreased to roughly one-tenth of the
parental expression levels, while the original 90%
decrease in GMD mRNA was retained. Monosaccharide
composition analysis showed that the ratio of non-fuco-
sylated oligosaccharides of the antibodies produced by
the four clones had increased significantly in each case
(i.e., up to 91%, 95%, 97%, and 98%), compared to those
of parental GMD siRNA-introduced clones (Table 2). The
increase in non-fucosylated product levels was cancelled
when the clones were cultured in the presence of L-fucose;
this cancellation was ascribed to the absence of a GMD
knockdown effect due to activation of the salvage pathway
of GDP-fucose synthesis. No significant effect on fucosyla-
tion levels in antibody-producing cells was observed with
a combination of either FUT8 and GFT or GMD and GFT
double knockdown.
Conversion of fucosylated antibody-producing cells to 
non-fucosylated antibody producers
To facilitate the double knockdown of FUT8 and GMD,
the siRNA tandem expression vector for targeting these
genes was generated and introduced into IgG1 antibody-
producing CHO/DG44 32-05-12 cells. Hygromycin-
resistant clones transformed by the vectors appeared with
a common transformation efficiency of approximately
1,500 per 1.6 × 106 electroporated cells. However, subse-
quent selection of LCA-resistant clones revealed clear dif-
ferences in the appearance of surviving colonies, as
compared to that of single siRNA-introduced clones
(Table 1). The ratio of LCA-resistant clones to hygromy-
cin-resistant clones transformed by the siRNA tandem
expression vector was much higher (more than triple)
than that of clones transformed by the vector bearing each
single siRNA expression cassette; approximately half of
the hygromycin-resistant clones showed resistance to
LCA, even in the culture condition containing L-fucose.
Among the resultant LCA-resistant clones, twenty were
randomly selected and expanded in medium lacking both
LCA and L-fucose. The mRNA expression of both target
genes, FUT8 and GMD, in each clone decreased to approx-
imately less than 20% of that of the parental clone (Fig.
2A). Out of twenty clones, eight exhibited relatively low
levels of both target genes, and these were selected for fur-
ther analysis of the oligosaccharide structure of the anti-
body products. The Fc oligosaccharide structures of the
Table 2: Monosaccharide composition of the N-linked oligosaccharide core structure of IgG1 from clones transformed with siRNA 
expression vectors
Clone Name siRNAa LFb Relative composition of monosaccharide Fucose(-)%d
Fucosec GlcNAc Mannose
32-05-12 - - 0.97 4.00 2.67 3
GMDb2 GMD - 0.22 4.00 2.52 78
GMDb5 GMD - 0.21 4.00 2.53 79
GMDb2-F3 GMD·FUT8 - 0.02 4.00 2.70 98
GMDb2-F5 GMD·FUT8 - 0.03 4.00 2.71 97
GMDb5-F2 GMD·FUT8 - 0.05 4.00 2.77 95
GMDb5-F4 GMD·FUT8 - 0.09 4.00 2.70 91
32-05-12 - + 0.94 4.00 2.56 6
GMDb2 GMD + 0.94 4.00 2.56 6
GMDb5 GMD + 0.92 4.00 2.60 8
GMDb2-F3 GMD·FUT8 + 0.19 4.00 2.52 81
GMDb2-F5 GMD·FUT8 + 0.21 4.00 2.54 79
GMDb5-F2 GMD·FUT8 + 0.19 4.00 2.55 81
GMDb5-F4 GMD·FUT8 + 0.33 4.00 2.68 67
aGMD, introduction of GMD siRNA expression vector; GMD·FUT8, introduction of FUT8 siRNA expression vector to GMD siRNA-introduced 
cells.
bLF, addition of 100 μM L-fucose into the culture medium.
cMolar ratios calculated vs. 4 GlcNAc.
dTotal percentage of non-fucosylated Fc oligosaccharides calculated by the formula (1-c) × 100.BMC Biotechnology 2007, 7:84 http://www.biomedcentral.com/1472-6750/7/84
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antibodies produced by these eight clones showed almost
complete non-fucosylation; there were no detectable L-
fucose residues among the products from six clones (Table
3). These six clones exhibited very low reactivity to LCA,
even after adaptation to serum-free medium, as was also
observed in the case of the FUT8-knockout CHO cell line
Ms705. The results obtained from two representative
clones, designated as FG1 and FG16, are shown in Fig.
2B–2E.
Serum-free fed-batch culture of siRNA-introduced cells 
producing non-fucosylated antibodies
Serum-free fed-batch culture of the clones transformed by
the FUT8 and GMD siRNA tandem expression vector was
carried out using 1L-scale spinner bioreactors with pH
and DO controls. Two FUT8 and GMD siRNA-introduced
clones, FG1 and FG16, and their parental IgG1-producing
clone, CHO/DG44 32-05-12, were adapted to serum-free
medium, and the performance of the fed-batch cultures
was compared in a head-to-head analysis (Fig. 3A, 3B).
The fed-batch cultures were maintained until the cell via-
bility decreased to less than 50%, which occurred at day
16 post-inoculation. Culture aliquots were taken at days
3, 6, 9, 12, 14, and 16 to analyze the cells and antibody
products. Two siRNA-introduced cell lines grew logarith-
mically, with a slight difference in the specific production
rate, maximum viable cell density, and the day upon
which the viable cell density reached the maximum level;
Analyses of clones transformed by the FUT8 and GMD siRNA tandem expression vector Figure 2
Analyses of clones transformed by the FUT8 and GMD siRNA tandem expression vector. The relative amounts of 
FUT8 (filled columns) and GMD (open columns) mRNA were quantified in the tandem siRNA expression vector-introduced 
LCA-resistant cells and parental cells (A). Each cell type was harvested after 3-day culture and the samples were analyzed by 
real-time PCR. Each mRNA amount was normalized to the amount of β-actin mRNA; the results are shown as the relative per-
cent with respect to the parental cells (100%). The LCA reactivity of cells (32-05-12 (B), Ms705 (C), FG1 (D), and FG16 (E)) 
was analyzed after adaptation of the cells to serum-free medium. Each cell type was harvested after 6-day culture and stained 
with FITC-labeled LCA (filled peak) or FITC-labeled streptavidin (open peak) as a negative control, and the results were ana-
lyzed by FACS.
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two siRNA-introduced hygromycin-resistant descendants
showed slightly slower growth and death rates than those
of the parent cells. However, the productivity of two
clones transformed by FUT8 and GMD siRNAs reached a
production level of approximately 1200 mg/L, which was
basically equivalent to that of the parental cells at the end
of the fed-batch culture period. During the culture period,
the levels of cellular FUT8 and GMD mRNAs in the two
siRNA-introduced clones remained at the original low
level, i.e., less than 20% of the parental level. Monosac-
charide composition analysis revealed that the two siRNA-
introduced clones stably produced non-fucosylated anti-
bodies throughout the culture period (Table 4). The oli-
gosaccharide profile analysis of products purified from
the final culture medium confirmed that the N-linked Fc
oligosaccharides of the products were of the biantennary
complex type, and the products from the two siRNA-intro-
duced clones fully lacked core fucosylation (Fig. 3D, 3E).
It was also confirmed that there was no significant change
in the oligosaccharide profile during the culture period,
and the non-fucosylated products showed two orders of
magnitude higher ADCC than the antibodies from the
parental CHO/DG44 cells, without any changes in anti-
gen binding (Fig. 4).
Discussion
The conversion of fucosylated therapeutic antibodies to
antibodies lacking the core fucose in the Fc is recognized
as an attractive approach for generating next-generation
therapeutics. In this study, we explored the possibility of
the high-frequency conversion of already-established
antibody-producing cells (1st-generation) to cells that pro-
duce antibodies fully lacking core fucosylation (2nd-gener-
ation) within a few months, while almost all original
features of the 1st-generation antibody-producing cells,
including cell growth and recombinant protein productiv-
ity, were retained. The present approach is expected to be
industrially useful for the establishment of a master cell
bank of antibody-producing cells for the rapid develop-
ment of 2nd-generation therapeutic antibodies.
Here, we focused on three key genes involved in the oli-
gosaccharide fucosylation pathway in mammalian cells
(FUT8, GMD, and GFT), and we identified an effective
siRNA of each gene among more than ten siRNA candi-
dates using a transient expression system with a target
gene-GFP fusion reporter construct, as previously reported
(data not shown) [32]. Every identified siRNA showed
high efficacy in terms of depressing the target mRNA to
levels of over 90%, when it was expressed in the form of
short hairpin siRNA under the control of U6 or the tRNA-
val promoter in antibody-producing cells in which the
siRNA expression unit was integrated in the genome. The
present results thus demonstrated that our established
siRNA expression system was able to sufficiently decrease
level of target mRNA to the current maximum level
achievable with RNAi technology. The levels of reduction
in Fc fucosylation among the products were found to vary,
depending on both target gene and clone, even when spe-
cific target genes were reduced to comparable levels in the
siRNA-introduced cells. Cellular phenotypic selection of
resistance to LCA was conducted to enrich transformants
with cellular features equivalent to those of FUT8-knock-
out cells. However, among clones transformed by either
siRNA alone, none produced fully lacking the core fucose
of the Fc. These results suggest that there is a fucosylation-
reducing limit associated with single-gene knockdown of
FUT8, GMD, and GFT using RNAi technology.
On the other hand, we clearly observed a noteworthy syn-
ergistic effect of double knockdown of FUT8 and GMD on
the fucosylation of products in antibody-producing cells
Table 3: Monosaccharide composition of the N-linked oligosaccharide core structure of IgG1 from clones transformed with the FUT8 
and GMD siRNA tandem expression vector
Clone Name siRNAa Relative composition of monosaccharide Fucose(-)%c
Fucoseb GlcNAc Mannose
32-05-12 - 0.96 4.00 2.60 4
FG1 + n.d. 4.00 2.58 100
FG3 + n.d. 4.00 2.65 100
FG4 + n.d. 4.00 2.63 100
FG7 + 0.02 4.00 2.57 98
FG9 + n.d. 4.00 2.61 100
FG13 + 0.02 4.00 2.55 98
FG16 + n.d. 4.00 2.57 100
FG20 + n.d. 4.00 2.62 100
aIntroduction of FUT8 and GMD siRNA tandem expression vector.
bMolar ratios calculated vs. 4 GlcNAc; n.d., not detectable.
cTotal percentage of non-fucosylated Fc oligosaccharides calculated by the formula (1-b) × 100.BMC Biotechnology 2007, 7:84 http://www.biomedcentral.com/1472-6750/7/84
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(Table 2), although neither the combination of FUT8 and
GFT, nor GMD and GFT double knockdown caused a sig-
nificant change. This synergistic effect was not accounted
for by the levels of mRNA regulation of target genes,
because no additive effect on the level of depression of
each target mRNA was observed with the FUT8 and GMD
double knockdown. Some previous studies have shown
that there is no functional redundancy in FUT8 and GMD,
although there is a fuctional redundancy in GFT
[28,30,33,34]. The loss of GFT seemed to be compensated
for by other genes possessing transporter activity. In ordi-
nary cell cultures, FUT8 is considered to be the only rate-
limiting step enzyme of fucosylation, since mammalian
cells retain excess endogenous intracellular GDP-fucose
[30,35]. In theory, the level of product fucosylation
should be controlled, either in a manner dependent on
endogenous FUT8 activity under cellular conditions of
abundant intracellular GDP-fucose, or in a manner
dependent on endogenous GMD activity under condition
of intracellular GDP-fucose starvation; these genes are not
currently believed to act in an interdependent manner.
However, the present results clearly demonstrated that
Serum-free fed-batch culture of clones transformed by the FUT8 and GMD tandem siRNA expression vector Figure 3
Serum-free fed-batch culture of clones transformed by the FUT8 and GMD tandem siRNA expression vector. 
Serum-free fed-batch culture using a 1L spinner bioreactor was carried out using cells transformed by the FUT8 and GMD tan-
dem siRNA expression vector (FG1 (open circles) and FG16 (filled circles)). The parental cell line 32-05-12 (filled squares) was 
cultured as a control. Viable cell density (A, solid lines), antibody concentration in the culture supernatant (A, dotted lines), and 
cell viability (B) were analyzed in the fed-batch culture. The oligosaccharide structures of the final products from 32-05-12 (C), 
FG1 (D), and FG16 (E) were analyzed using MALDI-TOF MS. The relative composition of each peak is shown as the relative 
amount to the total amount of oligosaccharide detected.
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residual FUT8 activity in single FUT8-gene knockdown in
mammalian CHO cells with a reduced substrate supply
due to a second GMD-gene knockdown yields an even
lower rate of fucose transfer to the oligosaccharides of the
products than that achieved with single FUT8-gene knock-
down cells. The intracellular GDP-fucose concentration in
the Golgi apparatus might have an effect on the function
of FUT8, although the precise reasons for the observed
synergy of FUT8 and GMD double knockdown in terms of
Table 4: Monosaccharide composition of the N-linked oligosaccharide core structure of IgG1 from clones transformed with the FUT8 
and GMD siRNA tandem expression vector during fed-batch culture
Clone Name Culture period (day) Relative composition of monosaccharide Fucose(-)%b
Fucosea GlcNAc Mannose
32-05-12 6 0.92 4.00 2.86 8
12 0.94 4.00 2.99 6
16 0.97 4.00 3.01 3
FG1 6 n.d. 4.00 2.85 100
12 n.d. 4.00 2.97 100
16 n.d. 4.00 2.92 100
FG16 6 n.d. 4.00 2.82 100
12 n.d. 4.00 2.96 100
16 n.d. 4.00 2.96 100
aMolar ratios calculated vs. 4 GlcNAc; n.d., not detectable.
bTotal percentage of non-fucosylated Fc oligosaccharides calculated by the formula (1-a) × 100.
Biological activity of antibodies from clones transformed with the FUT8 and GMD siRNA tandem expression vector Figure 4
Biological activity of antibodies from clones transformed with the FUT8 and GMD siRNA tandem expression 
vector. Lysis of antigen-expressing cells targeted by human PBMCs at a target:effector ratio of 1:20 in the presence of different 
antibody concentrations was quantified by detecting lactate dehydrogenase activity (A). The antigen-binding activity of the anti-
body was measured by ELISA (B). Antibody purified from the serum-free fed-batch cultures of cells transformed by the FUT8 
and GMD tandem siRNA expression vector, FG1 (open circles), FG16 (open squares), and the parental cell line 32-05-12 (filled 
circles) are shown. Cytotoxicity (%) and absorbance are indicated as the mean values ± SD of triplicates.
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reducing intracellular oligosaccharide fucosylation
remain unclear.
Single-step conversion of already-established antibody-
producing cells to non-fucosylated antibody producers by
double knockdown of FUT8 and GMD was attempted in
order to verify the industrial applicability of such a sys-
tem. Our transformation strategy was found to function
quite well; in brief, we introduced an siRNA tandem
expression vector for introducing the double knockdown
of FUT8 and GMD into antibody-producing cells, and we
carried out the cellular phenotypic selection of resistance
to LCA in the presence of L-fucose. We successfully estab-
lished antibody-producing clones in which no fuco-
sylated oligosaccharides were detected by either
monosaccharide composition or MALDI-TOF MS analy-
ses (Table 3, 4, Fig. 3D, 3E). Due to the very high conver-
sion frequency achieved with this approach, only two
months were required to complete all steps of the conver-
sion; the ratio of LCA-resistant clones to drug-resistant
clones transformed by the siRNA tandem expression vec-
tor was higher than that of clones transformed by each
single siRNA expression unit (Table 1), and six clones out
of the twenty LCA-resistant transformants randomly
selected were found to be converted precisely to the
desired clones (Table 3). The established converted clones
proved capable of consistently producing fully non-fuco-
sylated antibodies throughout the duration of a serum-
free fed-batch culture period; furthermore, a constant
ratio of F0G0, F0G1, and F0G2 oligosaccharides was
maintained until the end of the culture period (Fig. 3,
Table 4). The antibody productivity of the clones was also
found to be equivalent to that of the parental cells at the
end of the culture period. The purified antibodies
obtained from the cultures exhibited approximately 100-
fold higher ADCC compared to that of the original anti-
bodies obtained from the parental cells (Fig. 4). The sta-
bility of the converted clones was confirmed for a long
culture period of over 30 passages with stable integration
of the siRNA expression unit into the genome (data not
shown). The production and purification processes estab-
lished for the 1st-generation therapeutic antibodies could
be applied, with only marginal modifications, to establish
the 2nd-generation processes. Thus, the present approach
could provide substantial time and cost benefits for the
development of next-generation therapeutic antibodies.
Our preliminary experiments have also indicated that the
tandem siRNA expression vector designed for the double
knockdown of mouse FUT8 and GMD  also worked in
mouse myeloma cell lines NS0 and SP2/0.
Conclusion
The double knockdown of FUT8 and GMD in antibody-
producing cells is worth considering as a novel strategy for
generating therapeutic antibodies fully lacking core fuco-
sylation with enhanced ADCC. The tremendous cost- and
time-sparing advantages of this approach are expected to
facilitate the development of next-generation therapeutic
antibodies. This approach is based on our observation of
the synergistic effects of double knockdown of FUT8 and
GMD  on intracellular oligosaccharide fucose modifica-
tion in mammalian cells.
Methods
Cell lines
The dihydrofolate reductase-deficient CHO cell line,
CHO/DG44 [36], was obtained from Dr. Lawrence Cha-
sin of Columbia University (New York). A recombinant
mouse/human chimeric IgG1-producing CHO/DG44 cell
line, 32-05-12, generated as described previously [26],
was cultured in IMDM medium (Invitrogen, Carlsbad,
CA) containing 10% (v/v) dialyzed fetal bovine serum
(dFBS; Invitrogen) and 500 nM methotrexate (MTX;
Sigma-Aldrich, St. Louis, MO).
Construction of siRNA expression plasmids
An siRNA expression plasmid for targeting Chinese ham-
ster  GMD  (GenBank: AF525364), pPUR/GMDshB, was
generated as described below (Fig. 5A). The plasmid con-
tained a puromycin resistance gene as a selection marker
and a GMD short hairpin siRNA expression cassette con-
trolled by the human U6 promoter. The fragment of
human U6 promoter was prepared by PCR with KOD
polymerase (TOYOBO, Tokyo, Japan) from the plasmid
U6_FUT8_B_puro [26] using the primers 5'-
CCCAAGCTTG ATATCAAGGT CGGGCAGGAA GAG-
GGCCTAT-3' and 5'-GCTCTAGAGA TATCAAAAAA
GGTACCGAGC TCGGTGTTTC GTCCTTTCCA CA-3'. The
amplified human U6 promoter was inserted into pPUR
(Clontech, Mountain View, CA) at the PvuII site, and the
synthetic dsDNA coding short hairpin siRNA against
GMD  (5'-GAGCTCTATA AGAATCCACA GGCTCATATT
GAAGGCTTCC TGTCACCTTC AATATGAGCC TGTGGAT-
TCT TATAGGTACC-3') was inserted immediately down-
stream of the human U6 promoter at the SacI and KpnI
sites.
An siRNA expression plasmid for targeting Chinese ham-
ster  FUT8  [28], FUT8shRNA/lib3/pPUR, contained a
puromycin resistance gene as a selection marker and a
FUT8 short hairpin siRNA expression cassette controlled
by the human tRNAval promoter (Fig. 5B). The fragment of
human tRNAval promoter was prepared by PCR from the
plasmid ptRNA-SS [37] using the primers 5'-TTC-
CCAGTCA CGACGTT-3' and 5'-CAGGAAACAG CTAT-
GAC-3'. The amplified human tRNAval  promoter was
inserted into pPUR using the PvuII site, and the synthetic
dsDNA coding short hairpin siRNA against FUT8  (5'-
GAGCTCAAAT CCAAAAGAAT TTCATCTGCA TGTCTTT-
GGG GATCCCCAAA GACATGCAGA TGAAATTCTTBMC Biotechnology 2007, 7:84 http://www.biomedcentral.com/1472-6750/7/84
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TTGGATTTGT CGAC-3') was inserted immediately down-
stream of the human tRNAval promoter at the SacI and SalI
sites.
Another FUT8 siRNA expression plasmid, FT8lib3/pAGE
(Fig. 5C), was constructed by insertion of the FUT8 short
hairpin siRNA expression cassette from FUT8shRNA/lib3/
pPUR into pAGE249 [8] as follows. The FUT8 short hair-
pin siRNA expression cassette was excised from
FUT8shRNA/lib3/pPUR using the EcoRI and XhoI sites,
and its EcoRI terminus was converted to SmaI by subclon-
ing into pBlusecriptII KS(+) (Stratagene, La Jolla, CA). The
SmaI-XhoI fragment containing the FUT8  short hairpin
siRNA expression cassette was inserted into pAGE249 at
the NaeI and XhoI sites to construct FT8lib3/pAGE.
Two siRNA expression plasmids for targeting Chinese
hamster GFT (GenBank: AB222037), GFT_3G10/pPUR
and GFT_3G10/pAGE, were constructed by replacement
of the FUT8  dsDNA of FUT8shRNA/lib3/pPUR and
FT8lib3/pAGE, respectively, with the dsDNA coding short
hairpin siRNA against GFT  (5'-GAGCTCCCAA AGAG-
GGTGAG AAGAGTGCTA TTGGGATCCCAATAGCACTC
TTCTCACCCT CTTTGGGTCG AC-3').
Finally, an siRNA tandem expression plasmid for the dou-
ble knockdown of FUT8  and  GMD, FT8lib3_GMDB/
pAGE, was constructed by insertion of the GMD short
hairpin siRNA expression cassette (amplified by PCR from
pPUR/GMDshB using the primers 5'-CCGCTCGAGA
GCGCCTGATG CGGTATT-3' and 5'-CCGCTCGAGG
GACTTTCCAC ACCTGGT-3') into FT8lib3/pAGE at the
XhoI site (Fig. 5D). In this siRNA tandem expression vec-
Structure of siRNA expression plasmids Figure 5
Structure of siRNA expression plasmids. The GMD siRNA expression plasmid consisted of a puromycin resistance gene 
and a short hairpin siRNA expression cassette controlled by the human U6 promoter (A). FUT8 siRNA expression plasmids 
consisted of a puromycin or hygromycin resistance gene and a short hairpin siRNA expression cassette controlled by the 
human tRNAval promoter (B or C). The siRNA tandem expression plasmid consisted of a hygromycin resistance gene and two 
short hairpin siRNA expression cassettes targeting FUT8 and GMD (D). The transcribed shRNAs and tRNA-shRNA fusion 
product were processed into siRNAs by Dicer.
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tor, different PolIII promoters, tRNAval  and U6, were
designed to prevent unnecessary interference between the
two promoter systems.
Real-Time PCR analyses of GMD, FUT8, and GFT
In order to quantify the amounts of GMD, FUT8, and GFT
mRNA in the cells, real-time PCR analysis was carried out
using TaKaRa Ex Taq™ R-PCR Version (TaKaRa, Shiga,
Japan) and the following four sets of primers: 5'-ATC-
CTCGTCC TCCTTACTTA CC-3' and 5'-TCCAGCTGAC
CAAGAAATAG AG-3' for FUT8, 5'-AAGCCCAGGA AGGT-
GGCGCT CATCAC-3'and 5'-CACTAGTTGA GGCCTGG-
TAG AACTTCAC-3' for GMD, 5'-ATCATCATTG
GTGGTTTCTG G-3' and 5'-TCTCTTCATA GTAGAGCACG
GC-3' for GFT, and 5'-GATATCGCTG CGCTCGTCGT
CGAC-3' and 5'-CAGGAAGGAA GGCTGGAAGA GAGC-
3' for β-actin as an internal standard gene. Total RNA was
isolated from 5 × 106 cells using an RNeasy minikit (Qia-
gen, Hilden, Germany). Single-strand cDNA was synthe-
sized from 3 μg total RNA using the Superscript™ III first-
strand synthesis system for RT-PCR (Invitrogen). A 50-
fold diluted reaction mixture was used as a template. PCR
was carried out by heating the mixture at 94°C for 5 min
followed by 40 cycles of 94°C for 20 s, 65°C for 1 min,
and 72°C for 30 s in 20 μL of reaction mixture containing
1 unit of TaKaRa Ex Taq™ R-PCR Version, 1 μL of 2500-
fold diluted SYBR Green I (TaKaRa), 5 μL of the diluted
single-strand cDNA, and 6 pmol of primers using an ABI
PRISM 7700 sequence detection system (Applied Biosys-
tems, Foster City, CA) according to the manufacturer's
instructions. After PCR amplification, data acquisition
and analyses were performed using the GeneAmp 7700
sequence detection system version 1.7 (Applied Biosys-
tems).
LCA-staining analysis
Cells (2 × 105) were suspended in phosphate buffered
saline (PBS) containing 1% bovine serum albumin (BSA),
and either 2 μg/mL fluorescein isothiocyanate (FITC)-
labeled LCA (Vector Laboratories, Burlingame, CA) or 2
μg/mL FITC-labeled streptavidin (KPL, Gaithersburg,
MD) were added to the suspension. After incubation at
4°C for 30 min, 1 × 104 stained cells were analyzed by
FACScalibur (BD Biosciences, San Jose, CA) to evaluate
the reactivity to LCA on the cell surface.
Analyses of antibody-derived N-linked Fc oligosaccharides
Recombinant antibodies were purified from the serum-
free culture supernatant by Protein A-affinity chromatog-
raphy using MabSelect™ (Amersham Biosciences, Piscata-
way, NJ) and the samples were stored in 10 mM KH2PO4.
The concentration of purified antibodies was measured by
absorbance at 280 nm. The monosaccharide composition
of each purified IgG1 was characterized by modified high-
performance anion exchange chromatography (HPAEC)
as previously described [8]. The oligosaccharide profile of
each purified antibody was characterized by modified
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) in positive-ion
mode, as described previously [29].
Biological activity analysis of antibodies
An ADCC assay for each purified IgG1 was performed by
lactate dehydrogenase (LDH) release assay using human
peripheral blood mononuclear cells (PBMCs) from
healthy donors as effector cells at an E:T ratio of 20:1, as
described previously [26]. The antigen-binding activities
of the antibodies were measured by antigen-binding
ELISA, as previously described [26].
Isolation of FUT8, GMD, or GFT knockdown clones
An IgG1 antibody-producing clone, CHO/DG44 32-05-
12 (1.6 × 106 cells), was transformed by electroporation
with 10 μg of each siRNA expression vector linearized at
the FspI site (pPUR/GMDshB, FUT8shRNA/lib3/pPUR, or
GFT_3G10/pPUR). Transfectants were selected in 12 μg/
mL puromycin (Sigma-Aldrich) for 7 days, and then the
drug-resistant clones were subjected to 7-day selection
with 500 μg/mL LCA. The resultant LCA-resistant clones
were isolated and expanded in IMDM medium containing
10% (v/v) dFBS, 500 nM MTX, and 12 μg/mL puromycin.
Cells were collected for real-time PCR analysis after they
had grown to confluence in a tissue-culture flask (Greiner,
Frickenhausen, Germany). The serum-free culture super-
natants were recovered for antibody analysis after a 7-day
culture of the confluent cells in serum-free EX-CELL™ 301
medium (JRH Biosciences, Lenexa, KS).
Isolation of clones transformed by two siRNA expression 
vectors
The isolated GMD siRNA-introduced clones (1.6 × 106
cells) were electroporated again with 10 μg of FUT8 or
GFT siRNA expression vector linearized at the FspI site
(FT8lib3/pAGE or GFT_3G10/pAGE). Transfectants were
selected in 3 μg/mL puromycin and 400 μg/mL hygromy-
cin (Wako Pure Chemical Industries, Osaka, Japan) for 8
days, and then the drug-resistant clones were subjected to
7-day selection with 500 μg/mL LCA in the presence of
100 μM L-fucose. The resultant LCA-resistant clones were
isolated and expanded in IMDM medium containing 10%
(v/v) dFBS, 500 nM MTX, 3 μg/mL puromycin, and 400
μg/mL hygromycin for further real-time PCR and anti-
body analyses, as described above.
Conversion of antibody-producing cells to cells producing 
non-fucosylated antibodies
The CHO/DG44 32-05-12 (1.6 × 106) cells were trans-
formed by electroporation with 10 μg of the FUT8 and
GMD siRNA tandem expression vector linearized at the
FspI site (FT8lib3_GMDB/pAGE). Transfectants wereBMC Biotechnology 2007, 7:84 http://www.biomedcentral.com/1472-6750/7/84
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selected in 500 μg/mL hygromycin for 8 days, and then
the drug-resistant clones were subjected to 7-day selection
with 500 μg/mL LCA and 1 mM L-fucose. The resultant
LCA-resistant clones were isolated and expanded in
IMDM medium containing 10% (v/v) dFBS, 500 nM
MTX, and 500 μg/mL hygromycin for further real-time
PCR and antibody analyses as described above. The estab-
lished clones were adapted to serum-free medium EX-
CELL™ 302 (JRH Biosciences) supplemented with 6 mM
L-glutamine, 500 nM MTX, and 500 μg/mL hygromycin
for LCA-reactivity analysis and serum-free fed-batch cul-
ture.
Serum-free fed-batch culture
A 1L-scale spinner bioreactor (ABLE, Tokyo, Japan) was
employed to maintain controlled, serum-free, fed-batch
culture conditions of 35°C, pH 7.1, 50% DO. Each clone
was inoculated at 3.0 × 105 cells/mL in EX-CELL™302
medium supplemented with 6 mM L-glutamine and 500
nM MTX, and was fed with serum-free IMDM-based feed-
ing medium containing 5.3 μM human recombinant
insulin (Invitrogen) at days 3, 5, 7, 9, and 11 post-inocu-
lation to maintain a glucose content of approximately 5.0
g/L. Culture aliquots were drawn on days 3, 6, 9, 12, 14,
and 16 prior to addition of the feeding medium. Viable
cell density was measured with an automatic cell counter,
Vi-CELL™ XR (Beckman Coulter, Fullerton, CA), using
trypan blue exclusion. The antibody concentration in the
culture supernatant was measured by an enzyme-linked
immunosorbent assay (ELISA) specific for human IgG1,
as previously described [38].
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